Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep25 | Adrenal and Cardiovascular Endocrinology | ECE2023

Endocannabinoids in patients with adrenal incidentalomas. A new prognostic biomarker?

Mytareli Chrysoula , Athanasouli Fani , Karampela Athina , Papalexis Petros , Siampanopoulou Vasiliki , Lafioniatis Alexandros , Mantzourani Marina , Angelousi Anna

Background: The majority of adrenal incidentalomas (AIs) are benign non-functioning adrenocortical adenomas (NFAIs), yet not clinically silent. Possible autonomous cortisol secretion (PACS) can also be diagnosed in up to 50% of patients. Endocannabinoids (ECs) have recently been studied regarding their role in the hypothalamo-pituitary-adrenocortical (HPA) axis; however, data are scarce in humans.Aim: We aimed to assess hair EC [anandamide (AEA) and 2-ar...

ea0073aep49 | Adrenal and Cardiovascular Endocrinology | ECE2021

Hair cortisol levels in patients with adrenal incidentalomas compared to healthy controls

Athanasouli Fani , Mytareli Chrysoula , Andreadaki Evangelia , Petychaki Foteini , Savelli Akrivi , Asonitis Nikos , Anna Angelousi

BackgroundAdrenal incidentalomas (AI) are present in 3–10% of the general population. Up to 20% of them may have autonomous cortisol secretion (ACS). However, subclinical hypercortisolism isn’t clearly defined. The 1mg dexamethasone suppression test (ODST) is the most widely accepted for the screening of these patients. Recent data suggest that hair cortisol should be considered as a routine test for the screening of Cushing syndrome.<p cla...

ea0090ep173 | Calcium and Bone | ECE2023

The effect of Immune Checkpoint Inhibitors (ICIs) in Bone Metabolism: A case series analysis

Siampanopoulou Vasiliki , Angelousi Anna , Karampela Athina , Papalexis Petros , Lafioniatis Alexandros , Mytareli Chrysoula , Ziogas Dimitrios , Gogas Helen , Kassi Evanthia

Background: Immune checkpoint inhibitors (ICIs) constitutes a novel treatment for patients with melanoma. Endocrine-related adverse effects are now a distinctive clinical entity of ICIs, with hypophysitis and thyroiditis being the most common. Recent consensus doesn’t suggest routinely screening of bone mass indexes in patients on ICIs since data in the literature are scarce.Methods: Data regarding bone disease were retrospectively analysed in 118 p...

ea0099ep258 | Adrenal and Cardiovascular Endocrinology | ECE2024

Psychometric parameters and quality of life in patients with adrenal tumours

Charikleia Tasouli Elisavet , Mytareli Chrysoula , Andreadaki Evangelia , Thanasoula Foteini , Siampanopoulou Vasiliki , Karabela Athina , Papalexis Petros , Lafioniatis Alexandros , Angelousi Anna

Introduction: Neuropsychiatric disorders are common and well-studied in patients with overt hypercortisolism. However, data regarding patients with adrenal incidentalomas (AIs) are limited. The aim of our study is to assess the psychometric and quality of life status in individuals with benign adrenal tumours.Methods: Eighty-two patients diagnosed with AIs, encompassing 53 females and 29 males, with a total mean age of 64 years and 52controls (without AI...

ea0090ep593 | Endocrine-related Cancer | ECE2023

Endocrinopathies in oncological patients treated with immunotherapy: A real world data study

Angelousi Anna , Karampela Athina , Kazanas Spyridon , Papalexis Petros , Lafioniatis Alexandros , Siampanopoulou Vasiliki , Mytareli Chrysoula , Theochari Maria , Stephanou Dimitra , Ziogas Dimitrios , Gogas Helen

Background: Immune checkpoint inhibitors (ICIs) (anti-CTLA-4, PD-1 inhibitors, PD-L1 inhibitors) are considered a widely used therapeutic choice for several cancer types. However ICI therapy is frequently complicated by adverse events; endocrine toxicities are the most common ones.Methods: To assess in a retrospective observational study in a tertiary hospital the incidence and the characteristics of the immunotherapy-related endocrine adverse events (ir...

ea0099ep215 | Adrenal and Cardiovascular Endocrinology | ECE2024

Circulating micro-RNAs are valuable biomarkers for the diagnosis and surveillance of adrenocortical tumors

Mytareli Chrysoula , Kalotychou Vasiliki , Lafioniatis Alexandros , Siampanopoulou Vasiliki , Zografos Giorgos , Markou Athina , Papanastasiou Labrini , Fountas Athanasios , Mantzourani Marina , Kassi Eva , Kaltsas Gregory , Angelousi Anna

Introduction: Tumor-derived material, particularly micro-RNAs, have been identified in the bloodstream and hold promise as molecular markers for diagnosing and monitoring adrenocortical incidentalomas (AIs).Purpose: We examined selected circulating microRNAs (miR-483-5p, miR-210, miR-335, miR-22-3p), identified from microRNA profiling studies, as markers of malignancy or cortisol hypersecretion in a cohort of patients with AIs and controls in a clinical ...

ea0099ep334 | Calcium and Bone | ECE2024

Bone disorders in oncological patients treated with Immune-Checkpoint Inhibitors (ICIs)

Siampanopoulou Vasiliki , Angelousi Anna , Lyrarakis George , Karampela Athina , Papalexis Petros , Lafioniatis Alexandros , Mytareli Chrysoula , Tasouli Elisavet , Ziogas Dimitrios , Kassi Evanthia , Gogas Helen

Background: The use of immune checkpoint inhibitors (ICIs) has been lately established as a promising and effective treatment in several solid malignancies. Endocrine-related adverse effects are common, however their effects on bone metabolism is unknown.Methods: We retrospectively investigated the prevalence of bone-related complications in patients undergoing or completing treatment with ICIs. Epidemiological and clinical data from the medical files of...